NCT05662397 2025-02-04
A Study of HST-1011 Given as Monotherapy and in Combination With an Anti-PD1 Antibody
HotSpot Therapeutics, Inc
Phase 1/2 Active not recruiting
HotSpot Therapeutics, Inc
Chinese PLA General Hospital
Novartis
Sun Yat-sen University
Cancer Hospital of Guangxi Medical University